Cannabinoid Research Studies
Procana is accepting applications to further its own studies in these areas.
What is Alzheimers Disease?
Alzheimer's disease (AD) accounts for 60% to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually starts slowly and gets worse over time. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioral issues.
Procana Medical Studies [Apply]
Procana is accepting applicants to participate in medical studies of controlled dosage CBD for the treatment of Alzheimers Disease. “CBD” Cannabidiol subset studies will be derived from either Cannabis “Marijuana” or Industrial Hemp. Other medical studies may include ratios of “THC” Tetrahydrocannabinol derived from Cannabis, also known as Marijuana to study the treatment for Alzheimers Disease.
Procana does not warrant, nor does it have approval from the FDA to claim, diagnose or treat any illness or disease with its products containing Hemp, Cannabis or Marijuana with THC or CBD for the treatment of Alzheimers Disease.
To participate in these ongoing studies, please click here.
Most of the PubMed material consists of abstracts on preclinical research involving single cannabinoid molecules, test tubes, petri dishes, animal experiments, and in some cases human cell-line studies. Although all mammals have cell receptors that respond pharmacologically to cannabinoid compounds, data from animal experiments and other preclinical research is not always applicable to humans.
This data may include articles, surveys, studies or opinions related to THC and CBD from either Marijuana, Cannabis or Hemp in the use of Alzheimers Disease. This information is for research purposes only, and does not include the use of Procana products.